Explore By Subject Area   
Return Home
Menu

Lead Editorial

TrialHub Wins DPHARM Idol Disrupt 2025

TrialHub Wins DPHARM Idol Disrupt 2025

TrialHub wins DPHARM Idol Disrupt 2025 with a focus on adapting protocols to patients and accelerating recruitment.

Read More

Featured Editorial

How Merck Research Labs Is Evolving its Global Clinical Supply to Meet the Demands of Newer Modalities

Read More

Biogen on Digital Innovations to Increase Trial Access and Enhance Patient Experiences

Read More

What Clinical Research Means to Patients in Ukraine, and How Industry Sponsors Can Help

Read More

How CMOs can Leverage AI to Streamline Clinical Development

Read More

How the Roche RNAHub is Advancing Oligonucleotide Development and Delivery

Read More

Editorial by Category

Modernizing Clinical Trial Operations

View All
Three Ways to Help Cut Clinical Trial Timelines in Half: White Paper from McKinsey & Co
Three Ways to Help Cut Clinical Trial Timelines in Half: White Paper from McKinsey & Co
TrialHub Wins DPHARM Idol Disrupt 2025
TrialHub Wins DPHARM Idol Disrupt 2025
The Small Pharma Approach to Innovation, with Kyowa Kirin’s SVP of Global Clinical Operations
The Small Pharma Approach to Innovation, with Kyowa Kirin’s SVP of Global Clinical Operations
Driving Patient-Centered Trials with Outcome Measures
Driving Patient-Centered Trials with Outcome Measures

Immuno-Oncology and Cell Therapy

View All
Immuno-Oncology 360º Announces 2026 Featured Speakers and Key Topics for the 12th Annual Meeting in Boston
Immuno-Oncology 360º Announces 2026 Featured Speakers and Key Topics for the 12th Annual Meeting in Boston
Developing Nonactivated CAR T Therapy for Greater Persistence, Reduced Exhaustion and Enhanced In Vivo Expansion
Developing Nonactivated CAR T Therapy for Greater Persistence, Reduced Exhaustion and Enhanced In Vivo Expansion
Whole-Body Molecular Imaging’s Impact on Understanding Tumor Response and Advancing Immuno-Oncology (IO) Drug Development
Whole-Body Molecular Imaging’s Impact on Understanding Tumor Response and Advancing Immuno-Oncology (IO) Drug Development
Going After Immune Resistance and Metastases in Cancer Using RNA-Based Therapeutics
Going After Immune Resistance and Metastases in Cancer Using RNA-Based Therapeutics

Drug Delivery

View All
Implementing Sustainability Across the Drug Delivery Product Value Chain
Implementing Sustainability Across the Drug Delivery Product Value Chain
Self-Injection Device Manufacturing in a Dynamic World
Self-Injection Device Manufacturing in a Dynamic World
Empathy: The Strategic Edge in the AI Era with Fred Hassan
Empathy: The Strategic Edge in the AI Era with Fred Hassan
De-risking Combination Product Development Through Early Data-Driven Evaluation of Container Closure Systems
De-risking Combination Product Development Through Early Data-Driven Evaluation of Container Closure Systems

Patients as Partners in Clinical Research and Patient Access

View All
How Boehringer Ingelheim’s Site Engagement Academy Is Helping to Create Empathetic Site Partnerships for Patient Benefit
How Boehringer Ingelheim’s Site Engagement Academy Is Helping to Create Empathetic Site Partnerships for Patient Benefit
Collaborating for Change: Integrating Clinical Trials into Care Pathways
Collaborating for Change: Integrating Clinical Trials into Care Pathways
Operationalizing a New R&D Patient-Centricity Model at J&J
Operationalizing a New R&D Patient-Centricity Model at J&J
Involving Patient Insights in Medicine Development to Better Support Access and Decision-Making: Patients as Partners Europe 2025 Recap
Involving Patient Insights in Medicine Development to Better Support Access and Decision-Making: Patients as Partners Europe 2025 Recap

Biotech CMO/R&D Leadership

View All
Empathy: The Strategic Edge in the AI Era with Fred Hassan
Empathy: The Strategic Edge in the AI Era with Fred Hassan
Commercializing Therapies Requires Patient-Centricity and Advocacy
Commercializing Therapies Requires Patient-Centricity and Advocacy
How Investors Evaluate Biotech Companies and CMOs
How Investors Evaluate Biotech Companies and CMOs
One CMO’s Career Journey to Becoming CEO
One CMO’s Career Journey to Becoming CEO

CRAACO: Clinical Research as a Care Option

View All
How Boehringer Ingelheim’s Site Engagement Academy Is Helping to Create Empathetic Site Partnerships for Patient Benefit
How Boehringer Ingelheim’s Site Engagement Academy Is Helping to Create Empathetic Site Partnerships for Patient Benefit
Insights: Six Actions for Academic Health Systems to Achieve a High-Performing Clinical Trials Program
Insights: Six Actions for Academic Health Systems to Achieve a High-Performing Clinical Trials Program
How Dana-Farber Makes Clinical Trials Fit-For-Purpose in the Community Clinic Setting
How Dana-Farber Makes Clinical Trials Fit-For-Purpose in the Community Clinic Setting
How to Use Patient-Reported Outcomes to Bring Better Drugs Forward for Patients
How to Use Patient-Reported Outcomes to Bring Better Drugs Forward for Patients

Women Leadership in Biotech

View All
Commercializing Therapies Requires Patient-Centricity and Advocacy
Commercializing Therapies Requires Patient-Centricity and Advocacy
Staying Passionate about IO’s Potential and Investing in Biotechs Addressing IO’s Toughest Challenges
Staying Passionate about IO’s Potential and Investing in Biotechs Addressing IO’s Toughest Challenges
How Sponsors Can Help Sites with Payment, Staffing and Technology
How Sponsors Can Help Sites with Payment, Staffing and Technology
How Genentech’s Approach to Partnership and Licensing is Driving Innovation
How Genentech’s Approach to Partnership and Licensing is Driving Innovation

Subscribe for More Information

Please provide your contact information and select areas of interest to receive updates.